SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is trending after reporting quarterly results that exceeded expectations, driven by strength in its commercial segment and AI initiatives, sparking intense debate about the stock's valuation. The community is focused on the company's growth metrics, guidance, and the potential impact of AI on its future performance, while also arguing about whether the current price is justified. Some traders anticipate a continued rise, while others expect a pullback due to valuation concerns and broader market conditions.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to recent data from a confirmatory trial that failed to meet its primary endpoint, raising concerns despite an earnings beat; the community is actively debating the trial's impact and the company's future prospects. While some believe the selloff is an overreaction and a buying opportunity, others are worried about the long-term implications for Sarepta's PMO therapies and are looking to the upcoming conference call for clarity. Community members are also discussing potential for buyout.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors discuss recent Q3 earnings, which beat revenue estimates but missed on EPS. Community members are weighing the impact of the company's discussions with Novo Nordisk regarding Wegovy, with some expressing concerns about potential terms. Bullish sentiment remains due to subscriber growth and the potential for future gains, while others express skepticism, citing valuation and CEO actions.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as the community rallies around the project's active development and real-world partnerships. Discussions highlight the strength of the community and the meme's virality, with many expressing bullish sentiment and encouraging others to 'slap' it.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to anticipation of FDA's decision on Revuforj for relapsed/refractory NPM1 mutated acute myeloid leukemia, sparking discussions around the drug's market potential. The community is weighing the possibility of a buyout, with Incyte highlighted as a potential suitor, and debating Revuforj's competitive advantages. Traders are mapping out possible scenarios, from post-approval sell-offs to long-term gains based on strong revenue and drug performance.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is gaining attention as the community notes steady accumulation and resilient chart patterns, suggesting a potential breakout is on the horizon. The community is highlighting strong support levels and controlled price action, interpreting it as whales positioning for a significant move. Some users are comparing SHI to other tokens, noting similar setups and potential for growth within the crypto space.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab ($GRAB) is trending due to strong GMV momentum and news of a partnership with Alipay+, sparking bullish sentiment. The community is actively discussing accumulation plays and potential for a breakout, with some anticipating a run to higher price targets. Analysts cite the company's growth in on-demand services and financial services as key drivers, viewing it as an undervalued super-app in Southeast Asia.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as investors react to the company's earnings and upcoming ER call; while some express disappointment with the immediate market reaction, many highlight strong revenue growth and a substantial cash reserve. The community is actively discussing the importance of forward guidance from the earnings call and the potential impact of broader sector trends on the stock. Some traders are focusing on technical levels and options activity to gauge potential short-term movements.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals (TERN) is trending due to positive Phase 1 data for its leukemia drug TERN-701, which analysts believe could disrupt the CML treatment landscape, driving an upgrade from William Blair. The community is actively discussing the potential for a capital raise following the surge, with some wary of a possible "scam street" manipulation while others see a strong buying opportunity. Recent Oppenheimer and Mizuho ratings contribute to the bullish sentiment.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending amidst mixed sentiment, with the stock facing significant downward pressure and community frustration often directed at the CEO. Discussions revolve around the high short interest and speculation on potential catalysts like the upcoming earnings report, the Northern Data acquisition, and the launch of the Rumble Wallet. Some investors express optimism tied to the company's relationship with Tether and political affiliations, while others highlight concerns over profitability and user growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardelyx (ARDX) Reports Break-Even Earnings for Q3

Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +10.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?

Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to...

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.

Teladoc Health Expands Clarity Platform With Workplace Safety Tool

TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.

RBC Capital, Jefferies, and TD Cowen raised their price targets on BioCryst after the company announced plans to acquire Astria Therapeutics in a $700 million deal, with analysts calling the sell-off overdone and the combination strategically sound.<a href="https://stocktwits.com/symbol/BCRX">BioCryst shares</a> fell 8.8% to $6.42 on Tuesday, marking their fourth straight session of losses and the biggest single-day drop in nearly eight months, before edging up 1% in after-hours trading.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/ATXS">Astria Therapeutics’ stock</a> jumped 37.1% to $11.61 on Tuesday, its best day in nearly five years and highest level in almost a year, extending gains for a second straight session.RBC Capital raised its price target on BioCryst Pharmaceuticals to $15 from $14 and kept an 'Outperform' rating, saying Tuesday’s weakness in the stock presents a “compelling buying opportunity.” The firm said its confidence increased following BioCryst’s acquisition of Astria Therapeutics and discussions with management, adding that the deal sets up their franchise even better.Jefferies also raised its target on BioCryst to $15 from $14 while maintaining a 'Buy' rating. Analyst Maury Raycroft said the valuation reflects a discount due to a crowded hereditary angioedema (HAE) landscape, potential clinical and regulatory risks, and the need for FTC clearance, but added that the acquisition structure, under which Astria shareholders will own about 15% of the combined company, makes competing bids less likely.Meanwhile, TD Cowen reinstated coverage of BioCryst with a 'Buy' rating and a $30 price target, citing the company’s plan to acquire Astria’s Phase 3 injectable HAE prophylaxis candidate navenibart. The firm said navenibart, a plasma kallikrein inhibitor with strong proof of concept and high key opinion leader interest, is “de-risked.”&nbsp;BioCryst said on Tuesday that it will acquire Astria for $13 per share, valuing the company at about $700 million in enterprise value. The transaction, approved by both boards, is expected to close in the first quarter of 2026. BioCryst will finance the $8.55-per-share cash portion through a mix of existing cash and a new $550 million facility from Blackstone, with the rest paid in BioCryst stock.Astria’s navenibart, designed for quarterly or semi-annual injections, could expand BioCryst’s reach in the HAE market by complementing its existing oral therapy. BioCryst CEO Jon Stonehouse said the deal enables the company to “build out a comprehensive portfolio” that meets patient needs regardless of treatment preference.On Stocktwits, retail sentiment for both BioCryst and Astria was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said they had grown more positive on the Astria deal, noting that if the acquired asset is approved, it could make BioCryst’s revenue growth sustainable for years, which would help the company’s valuation even if some concerns remain.<stembedurl>https://stocktwits.com/luvpizza2/message/632344600</stembedurl>Another bullish user said the stock’s performance looked solid despite dilution, arguing that using undervalued shares to acquire a high-potential growth asset like Astria was a smart strategic move and could significantly boost BioCryst’s long-term worth.<stembedurl>https://stocktwits.com/Uptrending21/message/632308543</stembedurl>While BioCryst’s stock has declined 15% so far in 2025, Astria’s stock has risen 30% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

While BioCryst’s stock (BCRX) has declined 15% so far in 2025, Astria’s stock (ATXS) has risen 30% over the same period. (Photo credit: Getty Images)

BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play

The deal, valued at $700 million and backed by new Blackstone financing, is expected to close in early 2026.

Equity

Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

BioCryst Pharmaceuticals Inc. (BCRX) announced on Tuesday that it has struck a definitive deal to acquire Astria Therapeutics Inc.(ATXS), a clinical-stage biotech firm developing treatments for rare allergic and immunologic conditions.&nbsp;The agreement values Astria at $13.00 per share, totaling approximately $700 million in enterprise value. The acquisition, approved unanimously by both companies’ boards, is expected to close in the first quarter of 2026.To support the acquisition, BioCryst will fund the $8.55-per-share cash portion through a mix of cash on hand and a new financing facility from Blackstone, which offers up to $550 million in capital. The remainder of the consideration will be paid in BioCryst stock. Astria shareholders will own about 15% of the combined entity upon close.<a href="https://stocktwits.com/symbol/BCRX">BioCryst Pharmaceuticals’ stock</a> traded over 8% lower in Tuesday’s premarket.&nbsp;Astria’s flagship asset, navenibart, is a long-acting monoclonal antibody designed to prevent hereditary angioedema (HAE) attacks. Currently in Phase 3 trials, it offers a potential shift in care with its quarterly or semi-annual injection schedule. BioCryst aims to integrate navenibart alongside its existing oral therapy for HAE, creating a complementary treatment offering.“We believe this transaction gives BioCryst a perfect second product candidate that fits seamlessly with our HAE core competency and enables us to build out a comprehensive portfolio that could offer the most patient-friendly option, regardless of administration preference,” said CEO&nbsp; of BioCryst, Jon Stonehouse. “Navenibart can emerge as the injectable of choice for patients seeking infrequent, pain-free dosing, strong attack control, and a mechanism of action they know and understand.”The deal gives BioCryst access to a market of roughly 5,000 patients in the U.S. who currently rely on injectable prophylaxis.&nbsp;BioCryst Pharmaceuticals’ stock has lost over 5% in the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uuuu-stock-on-track-to-hit-14-year-highs-as-critical-minerals-sector-continues-to-see-strong-investor-interest/ch6mn1qR3mJ">UUUU Stock On Track To Hit 14-Year Highs As Critical Minerals Sector Continues To See Strong Investor Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of the biopharmaceutical company Curevac.

BioCryst To Acquire Astria Therapeutics In $700M Deal

The agreement values Astria at $13.00 per share, totaling approximately $700 million in enterprise value.

$BCRX Q3 &#39;25 Earnings Results &amp; Recap 
 
Biocryst reported Q3 2025 revenue of $159.1 million, missing estimates of $162.97M, and a non-GAAP EPS of $0.17, exceeding estimates of $0.04, while raising revenue guidance to $590-$600 million and lowering non-GAAP OpEx guidance to $430 to $440 million.

Stocktwits

Biocryst Pharmaceuticals Inc.

 Q3 '25 Earnings Results & Recap 
 
Biocryst reported Q3 2025 revenue of $159.1 million, missing estimates of $162.97M, and a non-GAAP EPS of $0.17, exceeding estimates of $0.04, while raising revenue guidance to $590-$600 million and lowering non-GAAP OpEx guidance to $430 to $440 million.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.02	--	--	N/A
Q3 '25	$0.04	$0.06	50.75%	BEAT
Q2 '25	$0.01	$0.02	185.71%	BEAT
Q1 '25	-$0.08	$0.00	100.00%	BEAT
Q4 '24	-$0.05	-$0.13	-182.61%	MISSED

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.